Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | PDE6D | O43924 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15000315 | 0.92 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3135 | 0.92 | ALDH1A1 (0.45) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1752130 | 0.89 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL7046242 | 0.88 | HMGCR (0.53) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13847948 | 0.88 | ALDH1A1 (0.42) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2880 | 0.87 | PTGS2 (0.45) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL7922156 | 0.86 | ALDH1A1 (0.43) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL15014916 | 0.86 | PTGS2 (0.46) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13847940 | 0.86 | ALDH1A1 (0.41) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13847937 | 0.85 | ALDH1A1 (0.41) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598484-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2016-06-29 | — | — | EP | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-8703944-B2 | Method for preparing rosuvastatin calcium intermediate | PORTON FINE CHEMICALS LTD. (CN) | 2014-04-22 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| US-8476432-B2 | Process for the preparation of HMG-COA reductase inhibitors and intermediates thereof | YUHAN CORPORATION (KR) | 2013-07-02 | — | — | US | disclosed |
| US-20130143908-A1 | METHOD FOR PREPARING ROSUVASTATIN CALCIUM INTERMEDIATE | PORTON FINE CHEMICALS LTD. (CN) | 2013-06-06 | — | — | US | disclosed |
| EP-2588474-A2 | PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF | Yuhan Corporation (KR) | 2013-05-08 | — | — | EP | disclosed |
| US-8394956-B2 | Process for preparing pyrimidine propenaldehyde | AUROBINDO PHARMA LTD. (IN) | 2013-03-12 | — | — | US | disclosed |
| US-20040181065-A1 | Process for preparing 2-amino-4-(4-fluorphenyl) -6-alkylpyrimidine-5-carboxylate | VEITH ULRICH (CH) | 2004-09-16 | — | — | US | disclosed |
| US-6710178-B2 | CYCLIZATION REACTION OF A 2-(-1-AMINO-1-(4- FLOUROPHENYL )METHYLENE)-4-ALKYL-3-OXO-ALKANOIC ACID ESTER AND AN N-CYANO-N-ALKYLALKANESULFONAMIDE | LONZA AG (CH) | 2004-03-23 | — | — | US | disclosed |
| US-20030199695-A1 | Preparation of 4-(4-flourophenyl)-6-alkyl-2-N-alkansulfonyl-N-alkylamino)pyrimidine-5-carboxylic acid ester. | VEITH ULRICH (CH) | 2003-10-23 | — | — | US | disclosed |
| US-6579984-B1 | Economical, industrially feasible | LONZA AG (CH) | 2003-06-17 | — | — | US | disclosed |
| EP-1194414-A1 | PROCESS FOR PREPARING 2-AMINO-4-(4-FLUORPHENYL)-6-ALKYLPYRIMIDINE-5-CARBOXYLATE | Lonza AG (CH) | 2002-04-10 | — | — | EP | disclosed |
| US-RE37314-E1 | Pyrimidine derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | disclosed |
| WO-2001004100-A1 | PROCESS FOR PREPARING 2-AMINO-4-(4-FLUORPHENYL)-6-ALKYLPYRIMIDINE-5-CARBOXYLATE | LONZA AG (CH) | 2001-01-18 | — | — | WO | disclosed |
| EP-0521471-B1 | Pyrimidine derivatives as HMG-CoA reductase inhibitors | SHIONOGI & CO (JP) | 2000-10-25 | — | — | EP | disclosed |
| US-5260440-A | Anticholesterol agents | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-11-09 | — | — | US | disclosed |
| EP-0521471-A1 | Pyrimidine derivatives as HMG-CoA reductase inhibitors | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, PCSK9, FAH | HMGCR 1/4885ALDH1A1 2643/4885CYP3A4 47/4885 |
| US-20130143908-A1 | METHOD FOR PREPARING ROSUVASTATIN CALCIUM INTERMEDIATE | HMGCR, PCSK9, CACNA1E | HMGCR 1/4885ALDH1A1 1226/4885CYP3A4 133/4885 |
| US-20030199695-A1 | Preparation of 4-(4-flourophenyl)-6-alkyl-2-N-alkansulfonyl-N-alkylamino)pyrimidine-5-carboxylic acid ester. | PFAS, F7, AFF1 | HMGCR 3328/4885ALDH1A1 299/4885CYP3A4 409/4885 |
| US-20040181065-A1 | Process for preparing 2-amino-4-(4-fluorphenyl) -6-alkylpyrimidine-5-carboxylate | ALKBH1, F7, CYP2B6 | HMGCR 3914/4885ALDH1A1 359/4885CYP3A4 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.